Neoadjuvant immunotherapy combined with stereotactic body radiation therapy for stage Ⅲ/N2 non-small cell lung cancer: Three cases reports
- VernacularTitle:新辅助免疫治疗联合体部立体定向放疗Ⅲ/N2期非小细胞肺癌三例
- Author:
Zhen WANG
1
;
Haoyu GU
2
;
Jing LUO
3
;
Xixu ZHU
1
;
Yong SONG
4
;
Yi SHEN
3
;
Yong QIANG
3
Author Information
1. Department of Radiation Oncology, General Hospital of Eastern Theater Command, Nanjing, 210016, P. R. China
2. Medical College, Nantong University, Nantong, 226006, Jiangsu, P. R. China
3. Department of Cardiothoracic Surgery, General Hospital of Eastern Theater Command, Nanjing, 210016, P. R. China
4. Department of Respiratory and Critical Medicine, General Hospital of Eastern Theater Command, Nanjing, 210016, P. R. China
- Publication Type:Journal Article
- Keywords:
Neoadjuvant therapy;
radiation therapy;
programmed cell death protein-1;
non-small cell lung cancer;
stereotactic body radiation therapy;
case report
- From:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
2023;30(08):1210-1216
- CountryChina
- Language:Chinese
-
Abstract:
We reported three cases of stageⅢ/N2 non-small cell lung cancer (NSCLC) treated with neoadjuvant immunotherapy and stereotactic body radiation therapy (SBRT) in our hospital, including 2 males and 1 female with a mean age of 65.7 years. The patients received two doses of the programmed cell death protein-1 inhibitor toripalimab after 1 week of SBRT. Thereafter, surgery was planned 4-6 weeks after the second dose. One patient achieved pathologic complete response, one achieved major pathologic response (MPR), and one did not achieve MPR with 20% residual tumor. There were few side effects of toripalimab combined with SBRT as a neoadjuvant treatment, and the treatment did not cause a delay of surgery.
